参泽舒肝胶囊联合多烯磷脂酰胆碱胶囊治疗非酒精性脂肪肝的临床研究  

Study of Shenzeshugan capsule combined with polyene phosphatidylcholine capsule in the treatment of nonalcoholic fatty liver

作　　者：陈杨 夏磊 龙华 CHEN Yang;XIA Lei;LONG Hua(Department of pharmacy,Zhujiang Hospital,Southern Medical University,Guangzhou Guangdong 510000,China;Department of hepatobiliary medicine,Balinyouqi hospital,Chifeng Inner Mongolia 025150,China)

机构地区：[1]南方医科大学珠江医院药剂科,广东广州510000 [2]内蒙古赤峰市巴林右旗旗医院肝胆内科,内蒙古赤峰025150

出　　处：《转化医学杂志》2022年第2期110-113,共4页Translational Medicine Journal

摘　　要：目的 研究参泽舒肝胶囊联合多烯磷脂酰胆碱胶囊治疗非酒精性脂肪肝的疗效。方法 将南方医科大学珠江医院2017年12月-2019年12月收治的非酒精性脂肪肝患者184例纳入本次研究,并以随机数表法将其分为试验组与对照组,每组92例。予以对照组患者多烯磷脂酰胆碱胶囊治疗,予以试验组患者多烯磷脂酰胆碱胶囊+参泽舒肝胶囊治疗。比较两组患者治疗后临床疗效、治疗前后肝功能指标及血脂水平、血清学指标水平变化、肝脏B超评分与肝脾CT比值指标、用药不良反应情况等指标。结果 治疗后,试验组患者临床有效率(95.65%)高于对照组(86.96%)(P<0.05);治疗前,两组患者谷丙转氨酶(aLanine aminotransferase,ALT)、谷草转氨酶(aspartate transaminase,AST)、高密度脂蛋白胆固醇(high density liptein cholesterol,HDL-C)、谷氨酰转肽酶(glutamyl transpeptidase,GGT)、总胆固醇(totalCholesterol,TC)、甘油三酯(triGlyceride,TG)、血清超氧化物歧化酶(superOxide dismutase,SOD)、丙二醛(malondialdehyde,MDA)和肿瘤坏死因子-α(tumor necrosis factor-α,TNF-α)、B超评分与肝脾CT比值等指标比较,差异无统计学意义(P>0.05);治疗后,两组患者ALT、AST、GGT水平降低,且试验组降低较明显(P<0.05);两组TC及TG水平降低,HDL-C水平升高(P<0.05);且试验组改善较明显(P<0.05);两组患者SOD升高,MDA和TNF-α水平降低(P<0.05);且试验组改善较明显(P<0.05);两组患者治疗后B超评分均下降,肝脾CT比值均提升,试验组治疗后B超评分低于对照组,肝脾CT比值高于对照组(P<0.05)。两组患者均无不良反应。结论 参泽舒肝胶囊联合多烯磷脂酰胆碱胶囊治疗非酒精性脂肪肝疗效显著,且安全可行。Objective To study the effect of Shenzeshugan capsule combined with polyene phosphatidylcholine capsule in the treatment of nonalcoholic fatty liver. Methods A total of 184 patients with non-alcoholic fatty liver disease admitted to Zhujiang Hospital of Southern Medical University from December 2017 to December 2019 were enrolled in this study and divided into experimental group and control group by random number table method, with 92 patients in each group. Patients in the control group were treated with polyene phosphatidylcholine capsules, and patients in the experimental group were treated with polyene phosphatidylcholine capsules combined with Shenzeshugan capsules. The clinical efficacy, liver function indexes, blood lipid levels, serological indexes, ratio indexes of liver B-ultrasound score and liver and spleen CT, adverse drug reactions, and other features were compared between the two groups.Results Before treatment, all clinical features between the two groups were comparable. After treatment, the clinical effective rate of the experimental group(95.65%) was significantly higher than that of the control group(86.96%, Pvalue<0.05). The levels of ALT, AST, and GGT in 2 groups were significantly decreased after treatment, and the experimental group decreased more(P value < 0.05). Compared to pre-treatment, the levels of TC, MDA, TNF-α, and TG were decreased while the levels of HDL-C and SOD were increased in both groups(P value < 0.05) with better improvement in the experimental group(P value < 0.05). After treatment, the b-ultrasound score in the experimental group was lower while the ratio of liver and spleen CT was higher than that of in the control group(P value<0.05).Conclusion Shenzeshugan capsule combined with polyene phosphatidylcholine capsule in the treatment of non-alcoholic fatty liver is effective, safe, and feasible, which is worthy of clinical application.

关 键 词：参泽舒肝胶囊 多烯磷脂酰胆碱胶囊 非酒精性脂肪肝 血脂水平 肝功能 

分 类 号：R575[医药卫生—消化系统]